lubiminol | 55784-92-4

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: lubiminol
• 英文别名: (3R,5S,6R,8S,10S)-10-(hydroxymethyl)-6-methyl-3-prop-1-en-2-ylspiro[4.5]decan-8-ol
• CAS: 55784-92-4
• 化学式: C₁₅H₂₆O₂
• 分子量: 238.37
• InChiKey: LOLOOEMMLLRJKC-ZSAUSMIDSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.87
• 拓扑面积：
  40.5
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  lubiminol 在 吡啶 、 chromium(VI) oxide 作用下， 以 二氯甲烷 、 苯 为溶剂， 反应 5.5h， 生成 isolubimin acetate
  参考文献：
  名称：

  Structure of Epilubimin, Epioxylubimin, and Isolubimin, Spirovetivane Stress Metabolites in Diseased Potato

  摘要：

  The isolation and structure elucidation of the title spirovetivane sesquiterpenes, stress metabolites produced in diseased potato tubers, are described.

  DOI：

  10.1246/bcsj.55.2424
• 作为产物：
  描述：

  lubimin 在 sodium tetrahydroborate 作用下， 生成 lubiminol
  参考文献：
  名称：

  Lubimin and Oxylubimin. The Structure Elucidation

  摘要：

  The isolation and structure elucidation of lubimin (3) and oxylubimin (4), stress metabolites from diseased white potato tubers, are described.

  DOI：

  10.1246/bcsj.50.1217

文献信息

• Method for treating a protozoal infection
  申请人：Reid Christopher Brian

  公开号：US10561650B2

  公开（公告）日：2020-02-18

  A method for reducing motility and number of L. donovani cells, said method comprising contacting the L. donovani cells with an effective amount of a composition, the composition comprising a combination of metronidazole and itraconazole, wherein the effective amount is sufficient to reduce motility of the L. donovani cells.

  一种降低唐诺瓦尼氏菌细胞活力和数量的方法，所述方法包括将唐诺瓦尼氏菌细胞与有效量的组合物接触，所述组合物包括甲硝唑和伊曲康唑的组合，其中有效量足以降低唐诺瓦尼氏菌细胞的活力。
• US20140271923A1
  申请人：——

  公开号：US20140271923A1

  公开（公告）日：2014-09-18
• METHOD FOR TREATING A PROTOZOAL INFECTION
  申请人：REID Christopher Brian

  公开号：US20160354370A1

  公开（公告）日：2016-12-08

  Patients inflicted with various clustering chronic diseases require treatment with multiple drugs having distinct mechanisms of action. Accordingly, patients with multiple conditions suffer from cumulative side effects of multiple drugs as well as drug-drug interactions. Embodiments, agents, compounds or drugs of the present invention, such as sesquiterpenes, e.g., Zerumbone, replace an equal or larger number of approved drugs during patient treatment. Examples of disorders prevented or ameliorated by administration of the formulations of this invention include but are not limited to inflammatory diseases that may be, oncological, genetic, ischemic, infectious, neurological, hematological, ophthalmological, rheumatoid, orthopedic, neurological, hematological, kidney, vascular, dermatological, gynecological, or obstetric. The present invention further relates to a method of identifying agents, compounds or drugs useful in preventing or treating CDCP related diseases and conditions as well as other disorders, diseases and conditions treatable or preventable by the same agents, compounds or drugs.
• Compositions of Natural Extracts and Use Thereof in Methods for Preventing or Treating Diseases
  申请人：REID Christopher Brian

  公开号：US20190224193A1

  公开（公告）日：2019-07-25

  A composition for reducing miR-3120 expression in a cell or tissue of a subject comprises at least one oil or extract selected from a group comprising an orange, frankincense and cannabis oil or extract. A method for reducing miR-3120 expression in a cell or tissue of a subject comprises administering to the subject a composition comprising at least one oil or extract selected from the group comprising an orange, frankincense and cannabis oil or extract.
• [EN] COMPOSITIONS COMPRISING SESQUITERPENE COMPOUNDS FOR USE IN THE PROPHYLAXIS OR TREATMENT OF PAIN<br/>[FR] COMPOSITIONS CONTENANT DES COMPOSES DE SESQUITERPENE A UTILISER POUR LA PROPHYLAXIE OU LE TRAITEMENT DE LA DOULEUR
  申请人：ZELPY 2549 PTY LTD

  公开号：WO2007066305A1

  公开（公告）日：2007-06-14

  [EN] According to the present application there is provided a preparation for use in the prophylaxis or treatment of pain in the human or animal body. The preparation is in the form of one or more sesquiterpene compounds or a composition containing at least 3 wt% of one or more sesquiterpene compounds.
  [FR] La présente invention concerne une préparation à utiliser pour la prophylaxie ou le traitement de la douleur chez un être humain ou un animal. La préparation se présente sous forme d'au moins un composé de sesquiterpène ou une composition contenant au moins 3 % en poids d'un ou de plusieurs composés de sesquiterpène.